Do analysts rate SYBX or ATNM?

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 410.31%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is SYBX or ATNM more profitable?

Synlogic's return on equity of -26.47% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media refer more to SYBX or ATNM?

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SYBX or LSTA?

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 346.43%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is SYBX or LSTA more profitable?

Synlogic's return on equity of -26.47% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Lisata Therapeutics N/A -103.54% -83.08%

Does the media refer more to SYBX or LSTA?

In the previous week, Lisata Therapeutics had 1 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for Synlogic. Lisata Therapeutics' average media sentiment score of 0.94 beat Synlogic's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SYBX or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is SYBX or NNVC more profitable?

Synlogic's return on equity of -26.47% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% NanoViricides N/A -87.90% -78.69%

Does the media refer more to SYBX or NNVC?

In the previous week, Synlogic and Synlogic both had 1 articles in the media. NanoViricides' average media sentiment score of 0.25 beat Synlogic's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DARE or SYBX?

Dare Bioscience presently has a consensus target price of $10.00, suggesting a potential upside of 373.93%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Dare Bioscience is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or SYBX more profitable?

Dare Bioscience's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Synlogic N/A -26.47% -18.00%

Does the media prefer DARE or SYBX?

In the previous week, Dare Bioscience had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Synlogic. Dare Bioscience's average media sentiment score of 0.93 beat Synlogic's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SYBX or CRVO?

CervoMed has a consensus price target of $22.60, indicating a potential upside of 512.47%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CervoMed 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Which has preferable earnings & valuation, SYBX or CRVO?

Synlogic has higher earnings, but lower revenue than CervoMed. Synlogic is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synlogic $8K 1,024.95 -$23.36M -$0.06 N/A CervoMed $4.01M 10.15 -$26.97M -$3.28 N/A

Is SYBX or CRVO more profitable?

Synlogic has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Synlogic's return on equity of -26.47% beat CervoMed's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% CervoMed -672.80% -136.08% -112.62%

Does the media prefer SYBX or CRVO?

In the previous week, CervoMed had 1 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for CervoMed and 1 mentions for Synlogic. CervoMed's average media sentiment score of 0.93 beat Synlogic's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Synlogic (SYBX) Competitors

$0.70 0.00 (0.00%)

As of 02:09 PM Eastern

Compare

SYBX vs. ATNM, LSTA, NNVC, DARE, and CRVO

Should you buy Synlogic stock or one of its competitors? MarketBeat compares Synlogic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synlogic include Actinium Pharmaceuticals (ATNM), Lisata Therapeutics (LSTA), NanoViricides (NNVC), Dare Bioscience (DARE), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

How does Synlogic compare to Actinium Pharmaceuticals?

Synlogic (NASDAQ:SYBX) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Synlogic has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 2.6% of Synlogic shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Synlogic's return on equity of -26.47% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Synlogic has higher earnings, but lower revenue than Actinium Pharmaceuticals. Synlogic is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,024.95	-$23.36M	-$0.06	N/A
Actinium Pharmaceuticals	$90K	341.57	-$48.82M	-$0.75	N/A

Actinium Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 410.31%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Synlogic and Synlogic both had 1 articles in the media. Synlogic's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Synlogic beats Actinium Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Synlogic compare to Lisata Therapeutics?

Synlogic (NASDAQ:SYBX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 2.6% of Synlogic shares are owned by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lisata Therapeutics had 1 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for Synlogic. Lisata Therapeutics' average media sentiment score of 0.94 beat Synlogic's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lisata Therapeutics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,024.95	-$23.36M	-$0.06	N/A
Lisata Therapeutics	$170K	180.06	-$16.59M	-$1.86	N/A

Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 346.43%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Synlogic's return on equity of -26.47% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Synlogic has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Summary

Lisata Therapeutics beats Synlogic on 9 of the 14 factors compared between the two stocks.

How does Synlogic compare to NanoViricides?

Synlogic (NASDAQ:SYBX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Synlogic's return on equity of -26.47% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
NanoViricides	N/A	-87.90%	-78.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Synlogic has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

In the previous week, Synlogic and Synlogic both had 1 articles in the media. NanoViricides' average media sentiment score of 0.25 beat Synlogic's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.4% of Synlogic shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NanoViricides has lower revenue, but higher earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,024.95	-$23.36M	-$0.06	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Summary

NanoViricides beats Synlogic on 7 of the 12 factors compared between the two stocks.

How does Synlogic compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dare Bioscience has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	30.69	-$13.40M	-$0.95	N/A
Synlogic	$8K	1,024.95	-$23.36M	-$0.06	N/A

Dare Bioscience presently has a consensus target price of $10.00, suggesting a potential upside of 373.93%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe Dare Bioscience is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dare Bioscience's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Synlogic	N/A	-26.47%	-18.00%

In the previous week, Dare Bioscience had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Dare Bioscience and 1 mentions for Synlogic. Dare Bioscience's average media sentiment score of 0.93 beat Synlogic's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Summary

Dare Bioscience beats Synlogic on 11 of the 15 factors compared between the two stocks.

How does Synlogic compare to CervoMed?

Synlogic (NASDAQ:SYBX) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Synlogic has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Synlogic's return on equity of -26.47% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
CervoMed	-672.80%	-136.08%	-112.62%

In the previous week, CervoMed had 1 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for CervoMed and 1 mentions for Synlogic. CervoMed's average media sentiment score of 0.93 beat Synlogic's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CervoMed has a consensus price target of $22.60, indicating a potential upside of 512.47%. Given CervoMed's stronger consensus rating and higher possible upside, analysts plainly believe CervoMed is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Synlogic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.68, meaning that its share price is 168% less volatile than the broader market.

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 2.6% of Synlogic shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Synlogic has higher earnings, but lower revenue than CervoMed. Synlogic is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,024.95	-$23.36M	-$0.06	N/A
CervoMed	$4.01M	10.15	-$26.97M	-$3.28	N/A

Summary

Synlogic and CervoMed tied by winning 8 of the 16 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYBX vs. The Competition

Export

Metric	Synlogic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.20M	$3.65B	$6.79B	$12.54B
Dividend Yield	N/A	2.20%	2.66%	6.15%
P/E Ratio	-2.70	21.49	27.46	25.28
Price / Sales	1,024.95	340.96	582.62	119.20
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.64	8.73	10.96	6.62
Net Income	-$23.36M	$23.87M	$3.57B	$336.83M
7 Day Performance	3.47%	3.31%	2.60%	2.58%
1 Month Performance	1.59%	3.33%	1.69%	0.48%
1 Year Performance	-40.59%	66.64%	36.01%	29.61%

Synlogic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYBX Synlogic	0.1107 of 5 stars	$0.70 flat	N/A	-44.8%	$8.20M	$8K	N/A	80	Gap Down
ATNM Actinium Pharmaceuticals	1.9753 of 5 stars	$1.01 -1.0%	$5.00 +395.0%	-30.0%	$31.69M	$90K	N/A	30
LSTA Lisata Therapeutics	2.9866 of 5 stars	$3.44 -0.9%	$15.00 +336.0%	+17.2%	$31.33M	$170K	N/A	30
NNVC NanoViricides	0.279 of 5 stars	$1.36 +3.8%	N/A	-1.4%	$31.26M	N/A	N/A	20
DARE Dare Bioscience	3.2844 of 5 stars	$2.08 +0.5%	$10.00 +380.8%	-11.7%	$31.16M	$1.03M	N/A	30	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYBX) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synlogic (SYBX) Competitors

SYBX vs. ATNM, LSTA, NNVC, DARE, and CRVO

How does Synlogic compare to Actinium Pharmaceuticals?

Summary

How does Synlogic compare to Lisata Therapeutics?

Summary

How does Synlogic compare to NanoViricides?

Summary

How does Synlogic compare to Dare Bioscience?

Summary

How does Synlogic compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synlogic (SYBX) Competitors

SYBX vs. ATNM, LSTA, NNVC, DARE, and CRVO

How does Synlogic compare to Actinium Pharmaceuticals?

Which has more risk & volatility, SYBX or ATNM?

Do institutionals & insiders believe in SYBX or ATNM?

Is SYBX or ATNM more profitable?

Which has preferable earnings & valuation, SYBX or ATNM?

Do analysts rate SYBX or ATNM?

Does the media refer more to SYBX or ATNM?

Summary

How does Synlogic compare to Lisata Therapeutics?

Do insiders and institutionals believe in SYBX or LSTA?

Does the media refer more to SYBX or LSTA?

Which has better valuation and earnings, SYBX or LSTA?

Do analysts recommend SYBX or LSTA?

Is SYBX or LSTA more profitable?

Which has more volatility & risk, SYBX or LSTA?

Summary

How does Synlogic compare to NanoViricides?

Is SYBX or NNVC more profitable?

Do analysts rate SYBX or NNVC?

Which has more volatility & risk, SYBX or NNVC?

Does the media refer more to SYBX or NNVC?

Do insiders & institutionals hold more shares of SYBX or NNVC?

Which has better earnings and valuation, SYBX or NNVC?

Summary

How does Synlogic compare to Dare Bioscience?

Do institutionals and insiders have more ownership in DARE or SYBX?

Which has higher valuation and earnings, DARE or SYBX?

Do analysts prefer DARE or SYBX?

Is DARE or SYBX more profitable?

Does the media prefer DARE or SYBX?

Which has more risk & volatility, DARE or SYBX?

Summary

How does Synlogic compare to CervoMed?

Is SYBX or CRVO more profitable?

Does the media prefer SYBX or CRVO?

Do analysts recommend SYBX or CRVO?

Which has more risk & volatility, SYBX or CRVO?

Do insiders & institutionals believe in SYBX or CRVO?

Which has preferable earnings & valuation, SYBX or CRVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools